Enrique Gómez-Figueroa1,2, Efrain Gutierrez-Lanz3, Alonso Alvarado-Bolaños3, Adriana Casallas-Vanegas3, Christian Garcia-Estrada3, Indhira Zabala-Angeles3, Arturo Cadena-Fernandez4, Rivas-Alonso Veronica3, Treviño-Frenk Irene5, José Flores-Rivera6,7. 1. National Institute of Neurology and Neurosurgery, Manuel Velasco Suarez, Insurgentes Sur 3877, Tlalpan, 14269, Mexico City, Mexico. enrique.gomez@innn.edu.mx. 2. The American British Cowdray Medical Center, Mexico City, Mexico. enrique.gomez@innn.edu.mx. 3. National Institute of Neurology and Neurosurgery, Manuel Velasco Suarez, Insurgentes Sur 3877, Tlalpan, 14269, Mexico City, Mexico. 4. The American British Cowdray Medical Center, Mexico City, Mexico. 5. National Institute of Medical Sciences and Nutrition, Mexico City, Mexico. 6. National Institute of Neurology and Neurosurgery, Manuel Velasco Suarez, Insurgentes Sur 3877, Tlalpan, 14269, Mexico City, Mexico. jflores@innn.edu.mx. 7. The American British Cowdray Medical Center, Mexico City, Mexico. jflores@innn.edu.mx.
Abstract
OBJECTIVE: Cyclophosphamide (CYC) is an alkylating agent with immunosuppressive effect by inhibiting DNA synthesis and producing apoptosis used in many autoimmune diseases, including multiple sclerosis (MS). Here, we analyze the efficacy of CYC treatment in relapsing-remitting (RRMS) and active secondary progressive MS (SPMS) in our center with a monthly scheme. METHODS: Patients with MS treated with CYC and a follow up of at least 36 months were eligible for inclusion. All participants had received a standard CYC regimen. The EDSS score mean annualized relapse rate (ARR) and progression index (PI) were measured as efficacy outcomes at 12, 24, and 36 months. Outcomes were also analyzed comparing disease course and activity. RESULTS: A total of 16 patients were included (50% male, 18.75% RRMS and 81.25% SPMS). EDSS remained stable along the follow-up period, with 62.5% improving or maintaining the same EDSS score at 12 months. PI decreased 14% and 21% at 12 and 24-36 months of follow-up, respectively. ARR decreased 20% after 12 months, 19% after 24 months, and 30.23% after 36 months. Median differences in ARR were higher in patients with high relapse activity (0.60 vs 0.07, p = 0.001) and malignant course (0.60 vs 0.17, p = 0.027). PI also differed with higher mean differences in patients with high relapse activity (0.70 vs 0.03, p = 0.016) and malignant course (1.17 vs 0.03, p = 0.003). CONCLUSIONS: CYC continues to be a valid therapeutic option, especially in regions with limited access to high-efficiency therapies particularly in patients with high relapsing activity and malignant course.
OBJECTIVE:Cyclophosphamide (CYC) is an alkylating agent with immunosuppressive effect by inhibiting DNA synthesis and producing apoptosis used in many autoimmune diseases, including multiple sclerosis (MS). Here, we analyze the efficacy of CYC treatment in relapsing-remitting (RRMS) and active secondary progressive MS (SPMS) in our center with a monthly scheme. METHODS:Patients with MS treated with CYC and a follow up of at least 36 months were eligible for inclusion. All participants had received a standard CYC regimen. The EDSS score mean annualized relapse rate (ARR) and progression index (PI) were measured as efficacy outcomes at 12, 24, and 36 months. Outcomes were also analyzed comparing disease course and activity. RESULTS: A total of 16 patients were included (50% male, 18.75% RRMS and 81.25% SPMS). EDSS remained stable along the follow-up period, with 62.5% improving or maintaining the same EDSS score at 12 months. PI decreased 14% and 21% at 12 and 24-36 months of follow-up, respectively. ARR decreased 20% after 12 months, 19% after 24 months, and 30.23% after 36 months. Median differences in ARR were higher in patients with high relapse activity (0.60 vs 0.07, p = 0.001) and malignant course (0.60 vs 0.17, p = 0.027). PI also differed with higher mean differences in patients with high relapse activity (0.70 vs 0.03, p = 0.016) and malignant course (1.17 vs 0.03, p = 0.003). CONCLUSIONS:CYC continues to be a valid therapeutic option, especially in regions with limited access to high-efficiency therapies particularly in patients with high relapsing activity and malignant course.
Entities:
Keywords:
Active multiple sclerosis; Cyclophosphamide; Efficacy
Authors: S L Hauser; D M Dawson; J R Lehrich; M F Beal; S V Kevy; R D Propper; J A Mills; H L Weiner Journal: N Engl J Med Date: 1983-01-27 Impact factor: 91.245
Authors: H L Weiner; G A Mackin; E J Orav; D A Hafler; D M Dawson; Y LaPierre; R Herndon; J R Lehrich; S L Hauser; A Turel Journal: Neurology Date: 1993-05 Impact factor: 9.910